Abstract: The present invention provides novel drug combinations, pharmaceutical compositions, as well as methods involving novel therapeutic regimes for targeting cancer stem cells, as well as methods of use thereof, for the treatment and management of cancerous and non-cancerous tumours in a patient. In particular, the present invention provides novel drug combinations and pharmaceutical compositions that target components of the Renin Angiotensin System shown to expressed by cancer stem cells.

Abstract: The present invention relates to methods and compositions for the treatment of hemangioma, and particularly, but not exclusively, methods and compositions for the treatment of infantile hemangioma. In certain aspects, the methods comprise locally administering an ACE inhibitor or an ATIIR2 antagonist to a subject. In other aspects, the methods comprise systemically administering two or more of an ACE inhibitor, a beta-blocker and an ATIIR2 antagonist. The present invention also relates to compositions that are suitable for local administration and comprise: an ACEi and a beta-blocker; an ACEi and an ATIIR2 antagonist; a beta-blocker and an AT11R2 antagonist; or, an ACEi, a beta-blocker, and an AT11R2 antagonist.

Abstract: The present invention provides novel drug combinations, pharmaceutical compositions, as well as methods involving novel therapeutic regimes for targeting cancer stem cells, as well as methods of use thereof, for the treatment and management of cancerous and non-cancerous tumours in a patient. In particular, the present invention provides novel drug combinations and pharmaceutical compositions that target components of the Renin Angiotensin System shown to expressed by cancer stem cells.

Abstract: The present invention provides a novel approach to cancer diagnosis and therapy of cancer by providing compositions and methods for the identification and specific targeting of the cancer stem cell populations present in a tumour to eradicate, or slow or prevent tumour (5) growth and spread, including the potential for tumour metastasis, by modulation of the Renin-Angiotensin System including, but not limited to, Renin Receptor, Angiotensin II Receptor (2) and a secreted form of the Renin Receptor.

Abstract: The present invention provides a novel approach to cancer diagnosis and therapy of cancer by providing compositions and methods for the identification and specific targeting of the cancer stem cell populations present in a tumor to eradicate, or slow or prevent tumor (5) growth and spread, including the potential for tumor metastasis, by modulation of the Renin-Angiotensin System including, but not limited to, Renin Receptor, Angiotensin II Receptor (2) and a secreted form of the Renin Receptor.

Abstract: The present invention provides a novel approach to the diagnosis, treatment and management of a fibrotic lesion by providing compositions and methods for the identification and specific targeting of the embryonic stem cell populations known to be associated with a fibrotic lesion, by modulation of the Renin-Angiotensin System.

Abstract: The present invention provides a novel approach to the diagnosis, treatment and management of vascular anomalies by providing compositions and methods for the identification and specific targeting of the embryonic stem cell populations associated with vascular anomalies, by modulation of the Renin-Angiotensin System expressed by the stem cells.

Abstract: The present invention provides a novel approach to cancer diagnosis and therapy of cancer by providing compositions and methods for the identification and specific targeting of the cancer stem cell populations present in a tumour to eradicate, or slow or prevent tumour (5) growth and spread, including the potential for tumour metastasis, by modulation of the Renin-Angiotensin System including, but not limited to, Renin Receptor, Angiotensin II Receptor (2) and a secreted form of the Renin Receptor.

Abstract: The invention relates to a device for estimating total antioxidant capacity (TAC) of a range of fluids and extracts. More particularly the invention relates to a device where the TAC is measured using lateral flow technology on a solid support. For example, the device may be a test strip.

Abstract: Oil obtained from the liver of hoki fish is a potent inhibitor of angiogenesis and inflammation, and a modulator of the immune system. Compositions containing hoki liver oil, or fractions thereof, are useful for treating diseases or disorders associated with angiogenesis and inflammation. Certain oil fractions are potent stimulants of the immune system whereas other fractions are potent suppressants of the immune system.

Abstract: An extract obtained from shark meat, which extract is capable of inhibiting angiogenesis in an animal. A process for obtaining the extract by contacting shark meat with a solvent, separating the resulting solution from the meat, then removing the solvent to give an extract which is an inhibitor of angiogenesis. The use of the extract for treatment of diseases associated with angiogenesis including cancer, retinopathy, inflammation, and arthritis.

Abstract: A process for obtaining an angiogenesis inhibitor and an angiogenesis activator from shark cartilage comprising, as the key step, the aqueous extraction of dried shark cartilage. The angiogenesis inhibitor obtained is more potent than shark cartilage not subjected to the extraction step. The angiogenesis inhibitor is particularly useful for the prevention or treatment of cancer. The angiogenesis activator is particularly useful for stimulating wound healing.